Evidence map›Paper›PMID 18957548›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2008

Variable breakpoints target PAX5 in patients with dicentric chromosomes: a model for the basis of unbalanced translocations in cancer.

Qian An, Sarah L Wright, Zoë J Konn, Elizabeth Matheson, Lynne Minto, Anthony V Moorman, Helen Parker, Mike Griffiths, Fiona M Ross, Teresa Davies and 4 more

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 89 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. The Pleiotropy ofInternational journal of molecular sciences · 2022
    Review
  6. Review
  7. Review
  8. Loss of Pax5 Exploits Sca1-BCR-ABLCancer research · 2018
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. The role of Pax5 in leukemia: diagnosis and prognosis significance.Medical oncology (Northwood, London, England) · 2015
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Qian AnCancer Genomics and Leukaemia Research Cytogenetics Groups, Cancer Sciences Division, University of Southampton, Southampton, SO16 6YD, United Kingdom.
Sarah L Wright
Zoë J Konn
Elizabeth Matheson
Lynne Minto
Anthony V Moorman
Helen Parker
Mike Griffiths
Fiona M Ross
Teresa Davies
Andy G Hall
Christine J Harrison
Julie A Irving
Jon C Strefford
Newcastle University · GBUniversity of Southampton · GBCancer Genomics Centre · NLSalisbury District Hospital · GBBirmingham Women's Hospital · GBSouthmead Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The search for target genes involved in unbalanced acquired chromosomal abnormalities has been largely unsuccessful, because the breakpoints of these rearrangements are too variable. Here, we use the example of dicentric chromosomes in B cell precursor acute lymphoblastic leukemia to show that, despite this heterogeneity, single genes are targeted through a variety of mechanisms. FISH showed that, although they were heterogeneous, breakpoints on 9p resulted in the partial or complete deletion of PAX5. Molecular copy number counting further delineated the breakpoints and facilitated cloning with long-distance inverse PCR. This approach identified 5 fusion gene partners with PAX5: LOC392027 (7p12.1), SLCO1B3 (12p12), ASXL1 (20q11.1), KIF3B (20q11.21), and C20orf112 (20q11.1). In each predicted fusion protein, the DNA-binding paired domain of PAX5 was present. Using quantitative PCR, we demonstrated that both the deletion and gene fusion events resulted in the same underexpression of PAX5, which extended to the differential expression of the PAX5 target genes, EBF1, ALDH1A1, ATP9A, and FLT3. Further molecular analysis showed deletion and mutation of the homologous PAX5 allele, providing further support for the key role of PAX5. Here, we show that specific gene loci may be the target of heterogeneous translocation breakpoints in human cancer, acting through a variety of mechanisms. This approach indicates an application for the identification of cancer genes in solid tumours, where unbalanced chromosomal rearrangements are particularly prevalent and few genes have been identified. It can be extrapolated that this strategy will reveal that the same mechanisms operate in cancer pathogenesis in general.

Indexed as

Chromosome BreakageGenes, NeoplasmAllelesBase SequenceChromosomes, Human, Pair 9Gene DosageHumansIn Situ Hybridization, FluorescenceModels, GeneticMolecular Sequence DataMutationOncogene Proteins, FusionPAX5 Transcription FactorPrecursor B-Cell Lymphoblastic Leukemia-LymphomaTranslocation, GeneticOncogene Proteins, FusionPAX5 protein, humanPAX5 Transcription Factor

Identifiers

PMID18957548
PMCPMC2579376
OpenAlexW2009697099

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.